Quarterly report which provides a continuing view of a company's financial position Submitted by amarin on Wed, 05/01/2019 - 10:53 Home Read more about Quarterly report which provides a continuing view of a company's financial position
Report of unscheduled material events or corporate event Submitted by amarin on Wed, 05/01/2019 - 10:53 Home Read more about Report of unscheduled material events or corporate event
Amarin Reports First Quarter 2019 Financial Results and Provides Update on Operations Submitted by amarin on Wed, 05/01/2019 - 09:00 Home Read more about Amarin Reports First Quarter 2019 Financial Results and Provides Update on Operations
New Drug Submission Filed for Vascepa® with Health Canada Submitted by amarin on Mon, 04/29/2019 - 10:00 Home Read more about New Drug Submission Filed for Vascepa® with Health Canada
Official notification to shareholders of matters to be brought to a vote ("Proxy") Submitted by amarin on Thu, 04/25/2019 - 11:04 Home Read more about Official notification to shareholders of matters to be brought to a vote ("Proxy")
REDUCE-IT clinical trial results | Brigham and Women's Hospital, 19-DEC-2018 Submitted by amarin on Wed, 04/24/2019 - 18:02 Home Read more about REDUCE-IT clinical trial results | Brigham and Women's Hospital, 19-DEC-2018
Amarin Q1 Results Conference Call Submitted by amarin on Wed, 04/24/2019 - 12:09 Home Read more about Amarin Q1 Results Conference Call
Amarin To Report First Quarter 2019 Results and Host Conference Call On May 1, 2019 Submitted by amarin on Wed, 04/24/2019 - 10:00 Home Read more about Amarin To Report First Quarter 2019 Results and Host Conference Call On May 1, 2019
A preliminary proxy statement providing notification matters to be brought to a vote Submitted by amarin on Mon, 04/15/2019 - 21:10 Home Read more about A preliminary proxy statement providing notification matters to be brought to a vote
Statement of changes in beneficial ownership of securities Submitted by amarin on Tue, 04/02/2019 - 00:28 Home Read more about Statement of changes in beneficial ownership of securities
